Topical Combo based on Pfizer and Novartis Drugs advances after Clearing early Clinical test
Synopsis: Pfizer’s JAK inhibitor Xeljanz and Novartis’ S1P modulator Gilenya both have their share of safety problems. But Vyne Therapeutics thinks it…
Synopsis: Pfizer’s JAK inhibitor Xeljanz and Novartis’ S1P modulator Gilenya both have their share of safety problems. But Vyne Therapeutics thinks it…
Summary : In just two short years, BioNTech will have more than doubled the size of its workforce at the German biologics…
Synopsis : Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication of new results from two laboratory studies…
Summary : Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit…
Synopsis : Sanofi and Exscientia announced a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates…
Summary : After a high-profile study turned up safety risks for Pfizer’s JAK inhibitor Xeljanz last year, the FDA put the entire…
Synopsis : Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep,…
Synopsis : Bharat Biotech has sought from the Drugs Controller General of India (DCGI) regular market approval for its COVID-19 vaccine Covaxin’,…
Summary : On the brink of two major approvals this year, Eli Lilly is laser-focused on diabetes and dementia. One market is…
Summary : Order up. Shortly after topping off supplies of COVID-19 drugs from Pfizer and GlaxoSmithKline, the U.S. has asked for a…